Presente y futuro del cáncer de seno HER2 positivo y triple negativo
DOI:
https://doi.org/10.56050/01205498.2314Palabras clave:
Cáncer de seno, Her2, Anticuerpo monoclonal, Cáncer de seno triple negativo, Tratamiento dirigido, Medicina de precisiónResumen
El cáncer de seno (BC) es la enfermedad más frecuente a nivel global y la segunda causa de muerte relacionada con cáncer. Desde el año 1990 se ha observado BC por su sigla en inglés; sin embargo, en Colombia, la supervivencia a 5 años sigue siendo baja. El entendimiento de los subtipos de cáncer y su terapéutica individual puede significar una oportunidad para mejorar el pronóstico de esta enfermedad en el país. Dentro de los subtipos descritos hay 2 que requieren una revisión en detalle: el subtipo HER2 positivo, un subtipo con alto riesgo de recaída, que con la introducción de tratamiento dirigido antiHER2 se convirtió en un ejemplo del tratamiento personalizado en cáncer, y el cáncer de seno triple negativo (TNBC), un grupo de tumores del seno que comparten una característica fenotípica común (la ausencia de expresión de HR y HER2) que tenía un Pronóstico pobre, con pocas opciones de tratamiento dirigido. La introducción de los anticuerpos monoclonales (MoAB por su sigla en inglés) significó un cambio en el paradigma terapéutico del BC HER2 positivo, mientras la introducción de medicamentos de inmunoterapia está cambiando la terapéutica del TNBC. Sin embargo, en ambos subtipos la aparición de anticuerpos conjugados con medicamentos supone un nuevo modelo terapéutico y una ventana de oportunidad para responder a las necesidades terapéuticas específicas para cada subgrupo.
Biografía del autor/a
William Armando Mantilla Duran, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
Unidad Funcional de Cáncer de Seno, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia.
Paolo Tarantino, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, Estados Unidos.
Universidad de Milán, Milán, Italia.
Referencias bibliográficas
Cancer Today [Internet]; [consultado agosto 15 de 2023]. Disponible en: https://gco.iarc.fr/today/home Acceso el 15 de agosto de 2023.
User S. [Internet]. Universidad del Valle; [consultado agosto 15 de 2023]. Disponible en. http://rpcc.univalle.edu.co Acceso el 15 de agosto de 2023.
Allemani C, Matsusa T, Di Carlo V, et al. Global survillance of trends and cancer survival 2000 – 14 (CONCORD 3) a analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 poppulation based registries in 71 countries. Lancet. 2018;391:1023-1075
Hendrick E, Helvie M, Monticciolo D. Breast cancer mortality rates have stop declining in US women younger than 40 years. Radiology. 2021;299:143–149.
Narod J, Iqbal J, Miller A. Why have breast mortality rates declined. J Can Pol. 2015;5:8–17.
Hortobayi G, De la Garza Salazar J, Pritchard K. et al. The global breast cancer burden: variations in epidemiology and survival. Clin breast cancer. 2005;6(5):391.
Peto R, Boreham J, Clark M, et al. IK and USA breast cancer deaths down 25 % in year 2000 at ages 20 – 69 years. Lancet. 2000;355(9217):1822.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
Sotiriou C, Pusztai L. Gene-Expression Signatures in Breast Cancer. N Engl J Med. 2009;360:790-800.
Pratt A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;(Suppl 2):S26–35.
Bastien R, Rodriguez-Lescure A, Ebbert M, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012; 5:44.
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61e70.
Wolff J, Somerfield M, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO - College of American Pathologist guideline update. J Clin Oncol 2023. 41 (22): 3876 – 3872.
Cronin KA, Harlan LC, Dodd KW, et al. Population- based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Canc Invest. 2010; 28:963e8.
Pegram, M. D, Konecny G., Slamon D. J. The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer. Cancer Treatment and Research. 2000;103:57–75.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177e82.
S. Burden, Y. Yarden, Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis, Neuron. 1997;18:847–855.
Troyer K.L., Lee D.C., Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network, J. Mammary Gland Biol. Neoplasia 2001. 6: 7–21.
Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell. 2002;110:775–787.
Citri A, Skaria K, Yarden J. The Deaf and dump: Biology of ErbB2 and ErbB3. Exp Cell Res. 2003;284(1):54–65.
arden Y, Sliwkowski M. Untangling the ErbB2 signalling network. Nat Rev Mol Cell Biol. 2001; 2:127–137.
Muss H, Thor AD, Berry DA, et al. c-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266.
Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-44.
Slamon D, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001; 344:783–792.
Perez E, Romond E, Suman V, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: planned joint analysis of overall survival from NSABP B31 and NCCTG N9831. J Clin Oncol. 2014;32:3744-3752.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant trastuzumab and pertuzumab in women with locally advanced inflammatory of early HER2 positive breast cancer (Neosphere) a randomized open label phase 2 trial. Lancet oncol. 2012;13(1):25-32.
van Mackelenbergh M, Loibl S, Untch M, et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2 positive early breast cancer. J Clin Oncol. 2023;41:2998-3008.
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-2284.
Von Minckwitz G, Procter M, De Azambua E, et al. Adjuvant pertuzumab and trastuzumab in ealy HER2 positive breast cancer. N Engl J Med. 2017;377:122–131.
Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
Rugo HS, Im S, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer. JAMA Oncol. 2021;573-584.
Blackwell KL, Burstein H, Storniolo A, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367-377.
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase 3 NALA trial. J Clin Oncol. 2020;38(27):3138– 3149.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.
von Minckwitz G, Huang CS, Mano M, et al Trastuzumab emtansine for residual invasive HER2 positive breast cancer. N Engl J Med. 2019;380:617-628.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610-621.
Costa R, Czerniecki B. Clinical development of immunotherapies for HER2+ breast cancer a review of HER2 directed antibodies and beyond, NPJ Breast cancer. 2020;6:10.
Baselga J. Treatment of HER2 overexpressing breast cancer. Ann Oncol. 2012;21(Suppl 1):S35-S41.
Schlam I, Swain S. HER2 positive breast cancer and tyrosine kinase inhibitors the time is now. NPJ Breast Cancer. 2021;7:56.
Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215.
Price-Schiavi SA, Jepson S, Li P, Arango M, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99:783-791.
Xu, X. De Angelis C, Burke K, et al. HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2(+) breast cancer. Clin. Cancer Res. 2017;23:5123–5134.
Lu Y, Zi X, Zhao Y, Mascarenhas D, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852-1857.
Schetinni F, Pratt A. Dissectionf the biology heterogeneity of HER2 positive breast cancer. Breast. 2021;59:350.
Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2 a truncated form of the HER2 receptor and response to antiHER2 therapies in breast cancer. Natl Cancer Inst. 2007;99(8):628-38.
Lander E, Rappazzo K, Huang LC, et al. Using the HER2/CEP 17 FISH ratio to predict pathologic complete response following neoadjuvant antiHER2 doublet therapy in HER2 positive breast cancer. Oncologist. 2023;28(2):123–130.
Villacampa G, Tung NM, Pernas S, et al. Association of HER2DX with pathologic complete response and survival outcomes in HER2 positive breast cancer. Ann Oncol. 2023;34(9):783-795.
Bauer K, Brown M, Cress R, et al. Descriptive analysis of ER negative PR negative and HER2 negative invasive breast cancer the so call triple negative phenoype. Cancer. 2007;109:1721–1728.
Cheang M, Vobuc D, Bajdik C, et al. Basal like breast cancer defined by five biomarkers has superior prognostic value than triple negative phenotype. Clin Cancer Res. 2008;14(5):1368-1376.
Martini R, Delpe P, Chu T, et al. African ancetry associated gene expression profiles in triple negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent. Cancer Discov. 2022;12:2530–2551.
Ortiz Valdes E, Rangel Escareño R, Matus Santos JA, et al. Characterization of triple negative breast cancer gene expression profiles in Mexican patients. Mol Clin Oncol. 2022;18(1):5.
O´brien K, Cole S, Tse CK, et al. Intrinsic breast cancer subtypes race and long term survival in the Carolina breast cancer study. Clin Cancer Res. 2010;16(24):6100–6110.
Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple negative breast cancer. Cancer. 2008;113:2638- 2645.
Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
Dent R, Trudeau M, Pritchard K, et al. Triple negative breast cancer clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
5rat A, Parker J, Karginova O, et al. Phenotype and molecular classification of the claudin low intrinsic subtype of breast cancer. Breast Cancer Research. 2010;12:R68.
Lehmann B, Bauer J, Chen X, el at. Identification of human triple negative breast cancer subtypes and preclinical models for selection of target therapies. J Clin Invest. 2011;121(7):2750–2767.
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. Clin Cancer Res. 2014;21(7):1688–1698.
Le Du F, Eckhardt B, Lim B, et al. Is the future of personalized therapy in triple negative breast cancer based on molecular subtype. Oncotarget. 2015;6:12890- 12908.
Sharma P. Biology and management of patients with triple negative breast cancer. The oncologist 2016. 21: 1050 – 1062.
Tutt A, Tovey H, Cheang, M, et al. A randomized phase III trial of carboplatin compared to docetaxel in BRCA1/2 mutated and pre specified triple negative breast cancer BRCAness, subgroups of the TNT trial. Nat Med. 2018;24(5):628–637.
Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.
von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple- negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 2014;15:747–756.
Gupta S, Nair NS, Haqwaldar RW, Vanmali V, Parmar V, Gulia S, et al. Addition of a platinum to the sequential taxanes-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer. A phase III randomized controlled trial. Cancer Research. 2023;83(5_Supplement).
Underhill C, Toulmonde M, Bonnefoi H. A review of the PARP inhibitors: from bench to bedside. Ann Oncol. 2011;22:268–279.
Rose M, et al. PARP inhibitors: clinical relevance, mechanism of action and tumor resistance. Frontiers in cell and development. Biology. 2020;8:1–22.
Robson, M. E. Im S, Senkus E, et al. OlympiAD extend follow up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Europ J Cancer. 2023;184:39–47.
Litton, J. K. Rugo H, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018. 379:753–763.
Tutt A, Garber J, Kaufman B, et al. Adjuvant Olaparib for patients with BRCA1 of BRCA2 mutated breast cancer. N Engl J Med. 2021;384:2394–2405.
Litton J, Scoggins M, Hess K, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388–394.
Waldman A, Fritz J, Lenardo M. A guide to cancer immunotherapy from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–668.
Schmid P, Rugo H, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced, or metastatic triple-negative breast cancer IMpassion130: Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(1):44–59.
Cortes J, Cescon D, Rugo H, et al. Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (Keynote 355) a randomized placebo controlled double blind phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümel S, Bergh J, et al. Pembrolizumab for early triple negative breast cancer. N Engl J Med. 2020;382(9):810–821.
Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149–1158.
Tolaney S, Barry W, Dang C, et al. Adjuvant paclitaxel and trastuzumab for node negative HER2 positive breast cancer. N Engl J Med. 2015; 372:134–141.
Cortes J, Perez Gonzalez JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá_de-Romaní S, et al. 3 year invasive disease free survival of the strategy based randomized phase II PHERGain trial evaluating chemotherapy (CT) de escalation in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Presentado en ASCO annual metting 2023. J Clin Oncol. 2023;41(17_suppl).
Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, et al. Tucatinib trastuzumab and capecitabine for the treament of HER positive metastatic breast cancer. N Engl J Med. 2020; 382(7):597–609.
Dumontet C, Reichert J, Senter P, et al. Antibody drug conjugates come of age in oncology. Nat Rev Drug Disc. 2023;22:641–661.
Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS8201a a novel anti human epidermal growth factor receptor 2 antibody drug conjugate in tumors with human epidermal growth factor receptor e heterogeneity. Cancer Sci. 2016;107:139–146.
Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan vs trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–1154.
Andre F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician´s choice in patients with HER2 positive metastatic breast cancer (DESTINY-Breast02) a randomized open label multicentre phase 3 trial. Lancet. 2023;401(10390):1773- 1785.
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2 low advanced breast cancer. N Eng J Med. 2023;387:9–20.
Shvartur A, Bonavida B, TROP2 and its overexpression in cancers regulation and clinical therapeutics implications. Gen Cancer. 2015;6:84–105.
Bardia A, Hurvitz S, Tolaney S, et al. Sacituzumab govitecan in metastatic triple negative breast cancer. N Eng J Med. 2021;384:1529–1541.
Cómo citar
Descargas
Publicado
Número
Sección
Licencia
Copyright
ANM de Colombia
Los autores deben declarar revisión, validación y aprobación para publicación del manuscrito, además de la cesión de los derechos patrimoniales de publicación, mediante un documento que debe ser enviado antes de la aparición del escrito. Puede solicitar el formato a través del correo revistamedicina@anmdecolombia.org.co o descargarlo directamente Documento Garantías y cesión de derechos.docx
Copyright
ANM de Colombia
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent.
